Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Amnioinfusion Initiative
This study is currently recruiting participants.
Verified by University of Milano Bicocca, November 2008
Sponsors and Collaborators: University of Milano Bicocca
Katholieke Universiteit Leuven
University of Milan
Catholic University, Italy
Information provided by: University of Milano Bicocca
ClinicalTrials.gov Identifier: NCT00787163
  Purpose

The aim of this study is to compare perinatal survival in patients presenting with early spontaneous PPROM and persistent oligohydramnios, managed either conservatively or with serial amnioinfusions.


Condition Intervention Phase
Oligohydramnios
Procedure: amnioinfusion
Phase III

U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Open Randomized Trial Comparing Perinatal Outcome Following Expectant Management Versus Amnioinfusion in PPROM <25 Wks With Persistent Oligohydramnios

Further study details as provided by University of Milano Bicocca:

Primary Outcome Measures:
  • Survival of neonates/infants at discharge after serial amnioinfusions compared to survival after expectant management [ Time Frame: discharge of every neonate from NICU ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Gestational age of delivery (main secondary outcome) [ Time Frame: time of delivery for every case ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 82
Study Start Date: September 2008
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
amnioinfusion
Procedure: amnioinfusion
serial amnioinfusions aimed at restoring amniotic fluid volume
2: No Intervention
expectant management

Detailed Description:

Early spontaneous Preterm Premature Rupture of Membranes (PPROM) is associated with high perinatal mortality. Due to pulmonary hypoplasia and preterm delivery, mortality exceeds 60% when PPROM occurs prior to 24 weeks. When oligohydramnios persists, it may raise to 90%. Morbidity in survivors is also significant. In uncontrolled series, serial amnioinfusions, which have acceptable invasiveness and are of limited complexity, mortality was reduced to 60%.

We propose an open, multicenter randomized trial comparing perinatal survival in patients presenting with early spontaneous PPROM and persistent oligohydramnios, managed either conservatively or with serial amnioinfusions. Inclusion criteria: Single pregnancy, early spontaneous PPROM < 24.3 weeks, oligohydramnios (deepest vertical pocket < 2 cm) for at least 4 days and no longer than 15 days at enrolment. The study is open and will be run through a dedicated password protected web site, and with a minimal number of outcome measures. Primary outcome: Survival till discharge from the NICU. Secondary outcomes: Latency time from PPROM to delivery, gestational age at birth, indication for delivery, number of days of ventilatory support, serious neurologic morbidity, neonatal sepsis prevalence, need for oxygen at 36 weeks post-conception.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients above 18 years, who are able to consent, with
  2. Singleton pregnancy
  3. with a normal structural examination as much as possible;
  4. At least 2 US examination after pPROM for gestational age confirmation and diagnosis of persistent oligohydramnios
  5. Follow up ultrasound examinations weekly in the treatment group
  6. Acceptance of randomisation and to comply with the protocol

Exclusion Criteria:

  1. Maternal contra-indications to intervention or prolongation of pregnancy, including severe medical conditions in pregnancy that make fetal intervention riskful;
  2. Preterm labour defined as contractions >6/hour associated with cervical changes, cervix shortened (<15 mm at randomization),
  3. Cervical cerclage in place
  4. Chorioamnionitis, defined as 2 or more of the following: maternal temperature>38 degrees, foul-smelling vaginal discharge, uterine tenderness, fetal tachycardia>170 bpm, white blood cell count >18,000
  5. Fetal structural anomaly detected at prenatal ultrasonography, or fetal chromosomal abnormalities involving autosomes
  6. Previous invasive procedure in this index pregnancy
  7. Fetal condition mandating immediate delivery
  8. Severe bleeding
  9. Maternal HIV and HCV infection
  10. Multiple gestation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00787163

Contacts
Contact: Anna Locatelli, MD +39 039 233 4720 anna.locatelli@unimib.it

Locations
Italy, Milano
University of Milano Bicocca, Ospedale san Gerardo Monza Recruiting
Monza, Milano, Italy, 20052
Contact: Anna Locatelli, MD     +390392334720     anna.locatelli@unimib.it    
Sponsors and Collaborators
University of Milano Bicocca
Katholieke Universiteit Leuven
University of Milan
Catholic University, Italy
Investigators
Principal Investigator: Anna Locatelli, MD University of Milano Bicocca
Study Chair: Patrizia Vergani, MD University of Milano Bicocca
  More Information

Responsible Party: University of Milano Bicocca ( Anna Locatelli )
Study ID Numbers: Amnioinfusion-001
Study First Received: November 6, 2008
Last Updated: November 6, 2008
ClinicalTrials.gov Identifier: NCT00787163  
Health Authority: Italy: Ethics Committee

Keywords provided by University of Milano Bicocca:
pPROM
oligohydramnios
amnioinfusion
prematurity
Early premature rupture of membranes in pregnancy

Study placed in the following topic categories:
Oligohydramnios
Pregnancy Complications
Rupture
Fetal Membranes, Premature Rupture

ClinicalTrials.gov processed this record on January 16, 2009